Real-world evaluation of ipilimumab (Ipi)/nivolumab (Nivo) in combination with two cycles of chemotherapy in patients (pts) with programmed death-ligand (PD-L1) negative advanced non-small cell lung cancer (aNSCLC): Interim results of the RW-9LA study

48P

  • Decoster, L.
  • Kerckhove, Vande S.
  • Ravoet, E.
  • Vervenne, F.
  • Vekens, K.

  • 1Department of Medical Oncology, UZ Brussel - Universitair Ziekenhuis Brussel, Jette, Belgium

    2UZ Brussel - Universitair Ziekenhuis Brussel, Jette, Belgium

    3Respiratory Division, UZ Brussel - Universitair Ziekenhuis Brussel, Jette, Belgium

Journal of Thoracic Oncology 20(3):p S41, March 2025. | DOI: 10.1016/S1556-0864(25)00243-6
Copyright © 2025 by the International Association for the Study of Lung Cancer
View full text|Download PDF